US-based biopharmaceutical company Synlogic announced yesterday it has completed its reverse merger with Nasdaq-listed biopharmaceutical firm Mirna Therapeutics after gaining the approval of Mirna’s shareholders.
The all-stock transaction was first revealed in May 2017. The combined company began trading on the Nasdaq Capital Market yesterday under the SYBX symbol and will operate as Synlogic.
Synlogic’s shareholders own approximately 82% of the combined entity, with the remainder held by Mirna’s stockholders.
Synlogic will focus on the development of drugs using…
